Abstracts Archive - Page 962 of 2607 - ACR Meeting Abstracts

Abstract Number: 1884 • ACR Convergence 2020
Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Jean Liew¹, Maria Castillo², Ethan Zaccagnino², Patricia Katz³, Nigil Haroon⁴ and Lianne Gensler⁵, ¹University of Washington, Seattle, WA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Response to the global coronavirus disease (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to how people go about their daily lives.…
Abstract Number: 1885 • ACR Convergence 2020
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
Emilce Schneeberger¹, Gustavo Citera², Dario Ponce de Leon³, Annette Szumski⁴, Kenneth Kwok⁵, Mariel Cutri⁶ and Maxime Dougados⁷, ¹Department of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³PFIZER, LIMA, Peru, ⁴Syneos Health, Princeton, ⁵Pfizer, New York, NY, ⁶Pfizer, Buenos Aires, Argentina, ⁷Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…
Abstract Number: 1886 • ACR Convergence 2020
Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH
Marllies Carbo¹, Davy Paap², Fiona Maas¹, Mark Siderius³, Hendrika Bootsma¹, Freke Wink³, Suzanne Arends³ and Anneke Spoorenberg³, ¹University Medical Centre Groningen, Groningen, Netherlands, ², Department of Rehabilitation Medicine, University of Medical Centre Groningen, Groningen, Netherlands, ³University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: The ASAS-EULAR recommendations for management of axial Spondyloarthritis (axSpA) includes that patients should be encouraged to exercise. There is no validated instrument for measuring…
Abstract Number: 1887 • ACR Convergence 2020
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Sinead Maguire¹, Phil Gallagher² and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²St Vincents University Hospital, UCD, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…
Abstract Number: 1888 • ACR Convergence 2020
Successful Evaluation of Spinal Mobility Measurements with the Epionics SPINE Device in Patients with Axial Spondyloarthritis Compared to Controls
David Kiefer¹, Xenofon Baraliakos², Daniela Adolf³, Varvara Chatzistefanidi⁴, Ilka Schwarze⁵, Uwe Lange⁶, Jan Brandt-Jürgens⁷, Edgar Stemmler⁸, Sabine Sartingen⁸ and Juergen Braun⁹, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ³StatConsult, Magdeburg, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, ⁵Rheumazentrum Leipzig, Leipzig, ⁶Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁷Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁸AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) comprising radiographic (r-) and non-radiographic (nr)-axSpA is often associated with loss of mobility and impaired physical function. Established assessments of spinal…
Abstract Number: 1889 • ACR Convergence 2020
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Yvette Farran¹, Alexis Ogdie², John Reveille³ and Mark Hwang⁴, ¹McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, University of Texas, Houston, TX, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…
Abstract Number: 1890 • ACR Convergence 2020
Daily Management of Patients with Axial Spondyloarthritis: Self-monitoring of Disease Activity with a Smartphone App Is Feasible – a Proof of Concept Study
Uta Kiltz¹, Robin Kempin¹, Jutta Richter², Anna Schlegel¹, Xenofon Baraliakos¹, Styliani Tsiami³, Ioana Andreica¹, Bjoern Buehring⁴, David Kiefer¹ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Duesseldorf, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany
Background/Purpose: Assessment and monitoring of disease activity and functioning is of major importance for the course of axial spondyloarthritis (axSpA). This is equally important for…
Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Ashit Syngle¹, Nidhi Garg² and Kanchan Chauhan¹, ¹Healing Touch City Clinic, Chandigarh, Chandigarh, India, ²Chitkara University, Rajpura, Punjab, India
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…
Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Jing Xue¹, Hongzhi Wang², Hongbin Li³, Hui Song⁴, Yasong Li⁵, Xiaofei Shi⁶, Hongjun Zhao⁷, Feng Wei⁸, Bing Wu⁹, Hui Xiao¹⁰, Yuhua Jia⁹, Fei Xiao⁹ and Huaxiang Wu¹, ¹The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, China (People's Republic), ²The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ³The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ⁴Beijing Jishuitan Hospital, Beijing, China (People's Republic), ⁵Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of science and technology, Luoyang, China (People's Republic), ⁷Xiangya Hospital of Central South University, Changsha, China (People's Republic), ⁸Jiangmen Central Hospital Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China (People's Republic), ⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 1894 • ACR Convergence 2020
Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain
Yuliya Afinogenova¹, Swetha Alexander², Andrew Haims³ and Abhijeet Danve⁴, ¹Yale University, Orange, CT, ²University of Connecticut, New Haven, ³Yale University, New Haven, CT, ⁴Yale University, Rocky Hill, CT
Background/Purpose: Delay in diagnosis of Axial Spondyloarthritis (axSpA) remains a significant unmet need and can be partially attributed to lack of timely rheumatology referral. Current…
Abstract Number: 1895 • ACR Convergence 2020
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Maria Llop¹, Mireia Moreno², Jordi Gratacós³, Victoria Navarro-Compán⁴, Eugenio De Miguel⁵, Pilar Font⁶, Teresa Clavaguera⁷, Luis Francisco Linares⁸, Beatriz Joven⁹ and Xavier Juanola¹⁰, ¹Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, ²Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁴Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁷Hospital Universitari Trueta, Girona, Spain, ⁸Hospital de la Arrixaca, Murcia, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
Abstract Number: 1896 • ACR Convergence 2020
No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Sofia Ramiro², Pedro M Machado³, Désirée van der Heijde⁴ and Floris van Gaalen⁵, ¹Leiden University Medical Center, Coimbra, Portugal, ²Leiden University Medical Center, Bunde, Netherlands, ³University College London, London, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA) it has been hypothesized that inflammation-driven bone loss triggers bone repair but at anatomically distinct sites of the same…
Abstract Number: 1897 • ACR Convergence 2020
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Anish Paudel¹, Rashmi Dhital², Dilli Poudel³, Anthony Donato¹ and Paras Karmacharya⁴, ¹Reading Hospital and Medical Center, West Reading, PA, ²Reading Hospital and Medical Center, West Reading, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester MN, ROCHESTER, MN
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the spine, leading to syndesmophyte formation, ankylosis, and osteoporosis. These factors have been associated…
Abstract Number: 1898 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau¹, Denis Choquette², Louis Bessette³, Isabelle Ferdinand¹, Boulos Haraoui⁴, Frédéric Massicotte¹, Jean-Pierre Pelletier², Jean-Pierre Raynauld², Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Édith Villeneuve¹ and Louis Coupal¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].